Michael C Bellavia1, Lea Nyiranshuti2,3,4, Joseph D Latoche2, Khanh-Van Ho5, Ronald J Fecek6,7, Jennifer L Taylor6, Kathryn E Day2, Shubhanchi Nigam8,9, Michael Pun5, Fabio Gallazzi5, Robert S Edinger2,10, Walter J Storkus1,6, Ravi B Patel11,12, Carolyn J Anderson13,14,15,16,17. 1. Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, 15213, USA. 2. Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA. 3. Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, 90095, USA. 4. RayzeBio Inc., San Diego, CA, 92121, USA. 5. Department of Chemistry, University of Missouri, Columbia, MO, 65211, USA. 6. Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, 15213, USA. 7. Department of Microbiology and Immunology, Lake Erie College of Osteopathic Medicine at Seton Hill, Greensburg, PA, 15601, USA. 8. Department of Radiology, University of Pittsburgh, Pittsburgh, PA, 15213, USA. 9. Eurofins Scientific, Philadelphia, PA, 19355, USA. 10. Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, 15213, USA. 11. Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, 15213, USA. patelr20@upmc.edu. 12. Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, 15213, USA. patelr20@upmc.edu. 13. Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, 15213, USA. carolyn.j.anderson@missouri.edu. 14. Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA. carolyn.j.anderson@missouri.edu. 15. Department of Chemistry, University of Missouri, Columbia, MO, 65211, USA. carolyn.j.anderson@missouri.edu. 16. Department of Radiology, University of Pittsburgh, Pittsburgh, PA, 15213, USA. carolyn.j.anderson@missouri.edu. 17. Department of Radiology, University of Missouri, Columbia, MO, 65211, USA. carolyn.j.anderson@missouri.edu.
Abstract
PURPOSE: Despite unprecedented responses to immune checkpoint inhibitors and targeted therapy in melanoma, a major subset of patients progresses and have few effective salvage options. We have previously demonstrated robust, selective uptake of the peptidomimetic LLP2A labeled with Cu-64 ([64Cu]-LLP2A) for positron emission tomography (PET) imaging in subcutaneous and metastatic models of B16F10 murine melanoma. LLP2A binds with high affinity to very late antigen-4 (VLA-4, integrin α4β1), a transmembrane protein overexpressed in melanoma and other cancers that facilitates tumor growth and metastasis. Yet B16F10 fails to faithfully reflect human melanoma biology, as it lacks certain oncogenic driver mutations, including BRAF mutations found in ≥ 50 % of clinical specimens. Here, we evaluated the PET tracer [64Cu]-CB-TE1A1P-PEG4-LLP2A ([64Cu]-LLP2A) in novel, translational BRAFV600E mutant melanoma models differing in VLA-4 expression-BPR (VLA-4-) and BPRα (VLA-4+). PROCEDURES: BPR cells were transduced with α4 (CD49d) to overexpress intact cell surface VLA-4 (BPRα). The binding affinity of [64Cu]-LLP2A to BPR and BPRα cells was determined by saturation binding assays. [64Cu]-LLP2A internalization into B16F10, BPR, and BPRα cells was quantified via a plate-based assay. Tracer biodistribution and PET/CT imaging were evaluated in mice bearing subcutaneous BPR and BPRα tumors. RESULTS: [64Cu]-LLP2A demonstrated high binding affinity to BPRα (Kd = 1.4 nM) but indeterminate binding to BPR cells. VLA-4+ BPRα and B16F10 displayed comparable time-dependent [64Cu]-LLP2A internalization, whereas BPR internalization was undetectable. PET/CT showed increased tracer uptake in BPRα tumors vs. BPR tumors in vivo, which was validated by significantly greater (p < 0.0001) BPRα tumor uptake in biodistribution analyses. CONCLUSIONS: [64Cu]-LLP2A discriminates BPRα (VLA-4+) vs. BPR (VLA-4-) melanomas in vivo, supporting translation of these BRAF-mutated melanoma models via prospective imaging and theranostic studies. These results extend the utility of LLP2A to selectively target clinically relevant and therapy-resistant tumor variants toward its use for therapeutic patient care.
PURPOSE: Despite unprecedented responses to immune checkpoint inhibitors and targeted therapy in melanoma, a major subset of patients progresses and have few effective salvage options. We have previously demonstrated robust, selective uptake of the peptidomimetic LLP2A labeled with Cu-64 ([64Cu]-LLP2A) for positron emission tomography (PET) imaging in subcutaneous and metastatic models of B16F10 murine melanoma. LLP2A binds with high affinity to very late antigen-4 (VLA-4, integrin α4β1), a transmembrane protein overexpressed in melanoma and other cancers that facilitates tumor growth and metastasis. Yet B16F10 fails to faithfully reflect human melanoma biology, as it lacks certain oncogenic driver mutations, including BRAF mutations found in ≥ 50 % of clinical specimens. Here, we evaluated the PET tracer [64Cu]-CB-TE1A1P-PEG4-LLP2A ([64Cu]-LLP2A) in novel, translational BRAFV600E mutant melanoma models differing in VLA-4 expression-BPR (VLA-4-) and BPRα (VLA-4+). PROCEDURES: BPR cells were transduced with α4 (CD49d) to overexpress intact cell surface VLA-4 (BPRα). The binding affinity of [64Cu]-LLP2A to BPR and BPRα cells was determined by saturation binding assays. [64Cu]-LLP2A internalization into B16F10, BPR, and BPRα cells was quantified via a plate-based assay. Tracer biodistribution and PET/CT imaging were evaluated in mice bearing subcutaneous BPR and BPRα tumors. RESULTS: [64Cu]-LLP2A demonstrated high binding affinity to BPRα (Kd = 1.4 nM) but indeterminate binding to BPR cells. VLA-4+ BPRα and B16F10 displayed comparable time-dependent [64Cu]-LLP2A internalization, whereas BPR internalization was undetectable. PET/CT showed increased tracer uptake in BPRα tumors vs. BPR tumors in vivo, which was validated by significantly greater (p < 0.0001) BPRα tumor uptake in biodistribution analyses. CONCLUSIONS: [64Cu]-LLP2A discriminates BPRα (VLA-4+) vs. BPR (VLA-4-) melanomas in vivo, supporting translation of these BRAF-mutated melanoma models via prospective imaging and theranostic studies. These results extend the utility of LLP2A to selectively target clinically relevant and therapy-resistant tumor variants toward its use for therapeutic patient care.
Authors: Gilad Halpert; Tom Eitan; Elena Voronov; Ron N Apte; Lea Rath-Wolfson; Michael Albeck; Yona Kalechman; Benjamin Sredni Journal: J Biol Chem Date: 2014-04-24 Impact factor: 5.157
Authors: F Stephen Hodi; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth F Grossmann; David F McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David R Minor; April K Salama; Matthew H Taylor; Patrick A Ott; Christine Horak; Paul Gagnier; Joel Jiang; Jedd D Wolchok; Michael A Postow Journal: Lancet Oncol Date: 2016-09-09 Impact factor: 41.316
Authors: Zachary A Cooper; Vikram R Juneja; Peter T Sage; Dennie T Frederick; Adriano Piris; Devarati Mitra; Jennifer A Lo; F Stephen Hodi; Gordon J Freeman; Marcus W Bosenberg; Martin McMahon; Keith T Flaherty; David E Fisher; Arlene H Sharpe; Jennifer A Wargo Journal: Cancer Immunol Res Date: 2014-04-29 Impact factor: 11.151
Authors: Klaus Strobel; Reinhard Dummer; Daniela B Husarik; Marisol Pérez Lago; Thomas F Hany; Hans C Steinert Journal: Radiology Date: 2007-08 Impact factor: 11.105